Five months after ending development of its own obesity treatment, Pfizer is accelerating its push into the rapidly growing field with a nearly $5 billion acquisition.

The COVID-19 vaccine and treatment maker said Monday that it will pay $47.50 in cash for each share of development-stage drugmaker Metsera. That represents a premium of more than 42% to Metsera's closing price Friday.

Pfizer also could pay an additional $22.50 per share depending on how Metsera's product pipeline develops.

Metsera Inc . has no products on the market, but its pipeline includes four programs in clinical development and one in mid-stage testing. Pfizer said the deal will add expertise and potential oral and injectable treatments.

Pfizer CEO Albert Bourla noted in a statement from the drugmaker that there a

See Full Page